Keyword: Charles Grassley
Citing Mylan's EpiPen, two senators introduced a bill cracking down on drug misclassifications that cost Medicaid millions in underpaid rebates.
Sticker prices in drug ads might be off the table again, thanks to some in the U.S. House of Representatives.
What do polarized senators dislike more than their partisan opponents? Pharma advertising, apparently.
Think President Trump's bid to slap price tags on drug ads is all talk? Think again. In recent days, the idea has gained steam—and bipartisan backing.
After pharma suffered an unexpected loss in this year's budget deal, the industry sees an opportunity to get some relief.
Congress hasn't made progress on pricing reform, but a group of lawmakers are pushing to reduce waste in pharmaceuticals.
It didn't take long for Congress to push back at Allergan's first-of-a-kind patent deal with the Saint Regis Mohawk Tribe.
Mylan has finished a settlement with the Department of Justice for $465 million relating to EpiPen’s misclassification on Medicaid.
Mylan has agreed to meet with Sen. Chuck Grassley, who is investigating a Medicaid drug misclassification that cost taxpayers more than $1.2 billion.
Mylan agreed to pay $465M to settle a federal probe into underpaid Medicaid rebates, but that's less than half the cost to taxpayers, HHS says.